Tag: pathways

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.

Wonderfeel’s 2025 Youngr™ update features a 900mg stabilized NMN dose with antioxidant co-factors, formulated to align with consumer interest in bioavailable, non-synthetic NAD+ wellness support.

Wonderfeel’s 2025 Youngr™ update features a 900mg stabilized NMN dose with antioxidant co-factors, formulated to align with consumer interest in bioavailable, non-synthetic NAD+ wellness support.

New 2025 At-Home Protocol Uses OTC Nerve Activation Tool to Reinforce Stability, Restore Confidence, and Help Reduce Fall Risk in Adults 60+

New 2025 At-Home Protocol Uses OTC Nerve Activation Tool to Reinforce Stability, Restore Confidence, and Help Reduce Fall Risk in Adults 60+

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

Featuring Sukre™ for GLUT-4 Receptor Support, Gluco6 Highlights Non-Synthetic Compounds and 2025 Trends in Plant-Based Glucose Wellness

Featuring Sukre™ for GLUT-4 Receptor Support, Gluco6 Highlights Non-Synthetic Compounds and 2025 Trends in Plant-Based Glucose Wellness

Bioma’s transparency-driven formula highlights XOS prebiotics, targeted Bifidobacterium strains, and tributyrin postbiotics—meeting rising consumer demand for non-synthetic gut health support without promotional claims.

Bioma’s transparency-driven formula highlights XOS prebiotics, targeted Bifidobacterium strains, and tributyrin postbiotics—meeting rising consumer demand for non-synthetic gut health support without promotional claims.

Now Reformulated With InnoSlim®, α-Lacys Reset®, and Capsimax® to Support Multi-Pathway Metabolic Function Without a Prescription

Now Reformulated With InnoSlim®, α-Lacys Reset®, and Capsimax® to Support Multi-Pathway Metabolic Function Without a Prescription

As consumers turn to ingredient-based mental clarity tools, Brain Defender emphasizes formulation transparency and non-clinical support in the evolving cognitive wellness space.

As consumers turn to ingredient-based mental clarity tools, Brain Defender emphasizes formulation transparency and non-clinical support in the evolving cognitive wellness space.

DELRAY BEACH, Fla., July 3, 2025 /PRNewswire/ -- What's fueling the shift from sterilization to scalability? The global single-use surgical instruments market, valued at US$5.60 billion...

MUMBAI, India, July 3, 2025 /PRNewswire/ -- Bound, India's leading creative education platform, announces the next edition of The Bound Publishing Course, a first-of-its-kind,...

Partnership now includes nearly 40 programmes in high-demand topics across flexible formats—from foundational online learning to advanced executive education ARLINGTON, Va. and OXFORD, England, July...

Invivyd Forms SPEAR (Spike Protein Elimination and Recovery) Study Group with Researches to Assess Effects of Monoclonal Antibody Therapy for Long COVID

As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52...